Place of insulin therapy in current approaches to the treatment of type 2 diabetes
https://doi.org/10.21518/2079-701X-2016-3-18-23
Abstract
Type 2 diabetes mellitus (T2DM) is a high risk factor for the development of macrovascular complications. Several large studies have demonstrated the fundamental role of early extensive blood glucose control in the prevention of these complications. An aggressive approach in achieving normoglycemia in patients with T2DM and existing macrovascular complications could lead to an increase in cardiovascular outcomes, which has a clear association with hypoglycemic conditions. Insulin therapy (IT) remains one of the most effective pharmacological treatments for diabetes provided adequate and timely prescription. The advent of long-acting insulin analogues helped not only to reduce the incidence of hypoglycemia as one of the most clinically relevant adverse events of IT, but also marked certain prospects in the prevention of type 2 diabetes in people with prediabetes.
About the Authors
O. Y. Gurova
First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Russian Federation
V. V. Fadeev
First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Russian Federation
References
1. Sowers JR. Diabetes meLLitus and cardiovascular disease in women. Arch intern Med, 1998, 158: 617-621.
2. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of Long-term complications in insuLin-dependent diabetes meLLitus. N. Engl. J. Med., 1993, 329: 977-86.
3. The DCCT/EDIC Study Research Group. Long-Term Effect of Diabetes and Its Treatment on Cognitive Function. N Engl J Med. May 2007; 356; 18; 1842-1852.
4. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive bLoodgLucose contro! with suLphonyLureas or insuLin compared with conventionaL treatment and risk of compLications in patients with Type 2 diabetes (UKPDS 33). Lancet, 1998, 352: 837-853.
5. Nathan DM, CLeary PA, BackLund JY et aL. Intensive diabetes treatment and cardiovascuLar disease in patients with type 1 diabetes. N. Engl. J. Med., 2005, 353: 2643-2653.
6. Stratton IM, AdLer AI, NeiL AW et aL. Association of gLycaemia with macrovas cuLar and micro-vascuLar compLications of type 2 diabetes (UKPDS 35): prospective observationaL study. BMJ, 2000, 321: 405-412.
7. Action to ControL CardiovascuLar Risk in Diabetes Study Group, Gerstein HC, MiLLer ME, Byington RP, et aL. Effects of intensive gLucose Lowering in type 2 diabetes. N. Engl. J. Med., 2008, 358: 2545-2559.
8. ADVANCE CoLLaborative Group, PateL A, MacMahon S, ChaLmers J et aL.: Intensive bLood gLucose controL and vascuLar outcomes in patients with type 2 diabetes. N. Engl. J. Med., 2008, 358: 2560-2572.
9. SkyLer S, BergenstaL R, Bonow R et aL. Intensive GLycemic ControL and the Prevention of CardiovascuLar Events: ImpLications of the ACCORD, ADVANCE, and VA Diabetes TriaLs. Diabetes Care, 2009, 32(1): 187-192.
10. HoLman RR, PauL SK, BetheL MA et aL. 10-year foLLow-up of intensive gLucose controL in type 2 diabetes. N. Engl J. Med., 2008, 359: 1577-1589.
11. Дедов И.И., Шестакова М.В., Александров А.А. и др. Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом» (7-й выпуск). Под ред. И.И. Дедова, М.В. Шестаковой (7-й выпуск). Cахарный диабет. 2015.
12. StumvoLL M, GoLdstein B, Van Haeften B, Pathohenesis of type 2 diabetes. Endocr.res, 2007, 32(1-2): 19-37.
13. Kostev K, MergenthaLer U. Time to insuLin initiation, gLucose controL and occurrence of diabetes reLated compLications in France, Germany and UK from 2005 to 2010. Diabetologia, 2011, 54, 1(SuppL. 1): S159.
14. CaLvert MJ et aL. Br J Gen Pract., 2007, 57(539): 455-460.
15. Ray KK, Seshasai SR, Wijesuriya S et aL. Effect of intensive controL of gLucose on cardiovascuLar outcomes and death in patients with diabetes meLLitus: a meta-anaLysis of randomised controLLed triaLs. Lancet, 2009, 373, 9677: 1765-1772.
16. Lepore M, PampaneLLi S, FaneLLi C et aL. Pharmacokinetics and pharmacodynamics of subcutaneous injection of Long-acting human insuLin anaLog gLargine, NPH insuLin and uLtra-Lente human insuLin and continuous infusion of insuLin Lispro. Diabetes, 2000, 49: 2142-48.
17. Heinemann L, Linkeschova R, Rave K, Hompesch B, SedLak M, Heise T. Time-action profiLe of the Long-acting insuLinanaLog insuLin gLargine (HOE901) in comparison with thoseof NPH insuLin and pLacebo. Diabetes Care, 2000, 23(5): 644-9.
18. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, WiLson CA. LesshypogLycemia with insuL-ingLarginein intensive insuLin therapy for type 1 diabetes. U.S. Study Group of InsuLin GLargine in Type 1 Diabetes. Diabetes Care, 2000, 23(5): 639-43.
19. Monami M, Marchionni N, Mannucci E. Long-acting insuLin anaLogues vs. NPH human insuLin in type 1 diabetes. Ameta- anaLysis. Diab Obes Metab., 2009, 11: 372-8.
20. Wang L, Wei W, Miao R, et aL. ReaL-worLd outcomes ofUS empLoyees with type 2 diabetes meLLitus treated withinsuLin gLargine or neutraL protamine Hagedorn insuLin: a comparative retrospective database study. BMJ Open, 2013, 3: e002348.
21. Origin TriaL Investigators. RationaLe, design, and baseLine characteristics for a Large internationaL triaL of cardiovascuLar disease prevention in peopLe with dysgLycemia: the ORIGIN TriaL (Outcome Reduction with an InitiaL GLargine Intervention). Am. Heart J., 2008, 155, 1: 26-32, 32.e1-6.
22. ORIGIN TriaL Investigators. CardiovascuLar and Other Outcomes Postinterventio With InsuLin GLargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care, 2015 Dec 17.
23. ORIGIN TriaL Investigators. BasaL insuLin and cardiovascuLar and other outcomes in dysgLy-cemia. N. Engl. J. Med., 2012, 367, 4: 319-328.
24. BLin P, LassaLLe R, Dureau-Pournin C, Ambrosino B,Bernard MA, AboueLfath A, et aL. InsuLin gLargine and risk of cancer: a cohort study in the French NationaL HeaLth care Insurance Database. Diabetologia, 2012, 55(3): 644-53.doi:10.1007/
25. Owens DR. GLargine and cancer: can we now suggest cLosure? Diabetes Care, 2012, 35(12): 2426-8. doi:10.2337/dc12-1968.
26. Dedov I.I., Shestakova M.V., Aleksandrov A.A. et al. Clinical guidelines: Algorithms of specialized medical care to patients with diabetes (vol. 7). Edited by I.I. Dedov, M.V. Shestakova (Vol. 7). Sakharniy Diabet. 2015
Review
For citations:
Gurova OY, Fadeev VV. Place of insulin therapy in current approaches to the treatment of type 2 diabetes. Meditsinskiy sovet = Medical Council. 2016;(3):18-23. (In Russ.) https://doi.org/10.21518/2079-701X-2016-3-18-23
Views:
644
Email this article 